These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification of tumor antigens with immunopeptidomics. Chong C; Coukos G; Bassani-Sternberg M Nat Biotechnol; 2022 Feb; 40(2):175-188. PubMed ID: 34635837 [TBL] [Abstract][Full Text] [Related]
4. Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery. Stutzmann C; Peng J; Wu Z; Savoie C; Sirois I; Thibault P; Wheeler AR; Caron E Cell Rep Methods; 2023 Jun; 3(6):100511. PubMed ID: 37426761 [TBL] [Abstract][Full Text] [Related]
5. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. Bassani-Sternberg M Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514 [TBL] [Abstract][Full Text] [Related]
6. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins. ElAbd H; Franke A Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028 [TBL] [Abstract][Full Text] [Related]
8. Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis. Sirois I; Isabelle M; Duquette JD; Saab F; Caron E J Vis Exp; 2021 Oct; (176):. PubMed ID: 34723952 [TBL] [Abstract][Full Text] [Related]
9. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Chong C; Müller M; Pak H; Harnett D; Huber F; Grun D; Leleu M; Auger A; Arnaud M; Stevenson BJ; Michaux J; Bilic I; Hirsekorn A; Calviello L; Simó-Riudalbas L; Planet E; Lubiński J; Bryśkiewicz M; Wiznerowicz M; Xenarios I; Zhang L; Trono D; Harari A; Ohler U; Coukos G; Bassani-Sternberg M Nat Commun; 2020 Mar; 11(1):1293. PubMed ID: 32157095 [TBL] [Abstract][Full Text] [Related]
10. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170 [TBL] [Abstract][Full Text] [Related]
11. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Flad T; Spengler B; Kalbacher H; Brossart P; Baier D; Kaufmann R; Bold P; Metzger S; Blüggel M; Meyer HE; Kurz B; Müller CA Cancer Res; 1998 Dec; 58(24):5803-11. PubMed ID: 9865739 [TBL] [Abstract][Full Text] [Related]
13. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887 [TBL] [Abstract][Full Text] [Related]
14. Benchmarking Bioinformatics Pipelines in Data-Independent Acquisition Mass Spectrometry for Immunopeptidomics. Shahbazy M; Ramarathinam SH; Illing PT; Jappe EC; Faridi P; Croft NP; Purcell AW Mol Cell Proteomics; 2023 Apr; 22(4):100515. PubMed ID: 36796644 [TBL] [Abstract][Full Text] [Related]
15. Antigen discovery for the development of cancer immunotherapy. Ahn R; Cui Y; White FM Semin Immunol; 2023 Mar; 66():101733. PubMed ID: 36841147 [TBL] [Abstract][Full Text] [Related]
17. IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma. Wahle M; Thielert M; Zwiebel M; Skowronek P; Zeng WF; Mann M Mol Cell Proteomics; 2024 Jan; 23(1):100689. PubMed ID: 38043703 [TBL] [Abstract][Full Text] [Related]
18. The impact of immunopeptidomics: From basic research to clinical implementation. Shapiro IE; Bassani-Sternberg M Semin Immunol; 2023 Mar; 66():101727. PubMed ID: 36764021 [TBL] [Abstract][Full Text] [Related]
19. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy. Minegishi Y; Haga Y; Ueda K Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459 [TBL] [Abstract][Full Text] [Related]
20. New insights and approaches for analyses of immunopeptidomes. Illing PT; Ramarathinam SH; Purcell AW Curr Opin Immunol; 2022 Aug; 77():102216. PubMed ID: 35716458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]